List of Eagle Pharmaceuticals, Inc. patents

Patents where

Current Assignee

Name

Eagle Pharmaceuticals, Inc.

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 9655898 Pharmaceutical compositions containing pemetrexed having extended storage stability	Patent 9655898 was granted and assigned to Eagle Pharmaceuticals, Inc. on May, 2017 by the United States Patent and Trademark Office.		Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	9655898	May 23, 2017
‌ US Patent 9572797 Formulations of bendamustine	Patent 9572797 was granted and assigned to Eagle Pharmaceuticals, Inc. on February, 2017 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	9572797	February 21, 2017
‌ US Patent 9572796 Formulations of bendamustine	Patent 9572796 was granted and assigned to Eagle Pharmaceuticals, Inc. on February, 2017 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	9572796	February 21, 2017
‌ US Patent 9000021 Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration	Patent 9000021 was granted and assigned to Eagle Pharmaceuticals, Inc. on April, 2015 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	9000021	April 7, 2015
‌ US Patent 9579384 Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration	Patent 9579384 was granted and assigned to Eagle Pharmaceuticals, Inc. on February, 2017 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	9579384	February 28, 2017
‌ US Patent 10010533 Formulations of bendamustine	Patent 10010533 was granted and assigned to Eagle Pharmaceuticals, Inc. on July, 2018 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	10010533	July 3, 2018
‌ US Patent 9265831 Formulations of bendamustine	Patent 9265831 was granted and assigned to Eagle Pharmaceuticals, Inc. on February, 2016 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	9265831	February 23, 2016
‌ US Patent 11103483 Formulations of bendamustine	Patent 11103483 was granted and assigned to Eagle Pharmaceuticals, Inc. on August, 2021 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	11103483	August 31, 2021
‌ US Patent 11590077 Fulvestrant formulations and methods of their use	Patent 11590077 was granted and assigned to Eagle Pharmaceuticals, Inc. on February, 2023 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	11590077	February 28, 2023
‌ US Patent 8431539 Formulations of daptomycin	Patent 8431539 was granted and assigned to Eagle Pharmaceuticals, Inc. on April, 2013 by the United States Patent and Trademark Office.		Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	8431539	April 30, 2013
‌ US Patent 9572888 Formulations of bendamustine	Patent 9572888 was granted and assigned to Eagle Pharmaceuticals, Inc. on February, 2017 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	9572888	February 21, 2017
‌ US Patent 9034908 Formulations of bendamustine	Patent 9034908 was granted and assigned to Eagle Pharmaceuticals, Inc. on May, 2015 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	9034908	May 19, 2015
‌ US Patent 9597397 Formulations of bendamustine	Patent 9597397 was granted and assigned to Eagle Pharmaceuticals, Inc. on March, 2017 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	9597397	March 21, 2017
‌ US Patent 9597398 Formulations of bendamustine	Patent 9597398 was granted and assigned to Eagle Pharmaceuticals, Inc. on March, 2017 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	9597398	March 21, 2017
‌ US Patent 9572887 Formulations of bendamustine	Patent 9572887 was granted and assigned to Eagle Pharmaceuticals, Inc. on February, 2017 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	9572887	February 21, 2017
‌ US Patent 9144568 Formulations of bendamustine	Patent 9144568 was granted and assigned to Eagle Pharmaceuticals, Inc. on September, 2015 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	9144568	September 29, 2015
‌ US Patent 10052385 Formulations of bendamustine	Patent 10052385 was granted and assigned to Eagle Pharmaceuticals, Inc. on August, 2018 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	10052385	August 21, 2018
‌ US Patent 8609707 Formulations of bendamustine	Patent 8609707 was granted and assigned to Eagle Pharmaceuticals, Inc. on December, 2013 by the United States Patent and Trademark Office.		Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	8609707	December 17, 2013
‌ US Patent 11179468 Fulvestrant formulations	Patent 11179468 was granted and assigned to Eagle Pharmaceuticals, Inc. on November, 2021 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	11179468	November 23, 2021
‌ US Patent 7687516 Alcohol free formulation of argatroban	Patent 7687516 was granted and assigned to Eagle Pharmaceuticals, Inc. on March, 2010 by the United States Patent and Trademark Office.		Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	7687516	March 30, 2010
‌ US Patent 7589106 Alcohol free formulation of argatroban	Patent 7589106 was granted and assigned to Eagle Pharmaceuticals, Inc. on September, 2009 by the United States Patent and Trademark Office.		Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	7589106	September 15, 2009
‌ US Patent 10363259 Fulvestrant formulations	Patent 10363259 was granted and assigned to Eagle Pharmaceuticals, Inc. on July, 2019 by the United States Patent and Trademark Office.		Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	10363259	July 30, 2019
‌ US Patent 12115164 Pemetrexed formulations	Patent 12115164 was granted and assigned to Eagle Pharmaceuticals, Inc. on October, 2024 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	12115164	October 15, 2024
‌ US Patent 11872214 Formulations of Bendamustine	Patent 11872214 was granted and assigned to Eagle Pharmaceuticals, Inc. on January, 2024 by the United States Patent and Trademark Office.	Eagle Pharmaceuticals, Inc.	Eagle Pharmaceuticals, Inc.	United States Patent and Trademark Office	11872214	January 16, 2024

24 results

0 selected

24 results

0 selected